1. Vedantam S. Antidepressant makers withhold data on children. Washington Post. 2004 Jan 29.
2. Melander H., Ahlqvist-Rastad J., Meijer G., et al. Evidence b(i)ased medicine – selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ. 2003; 326: 1171–3.
3. Melander H. [Selective reporting – greater problem than selective publishing?] L?kartidningen. 2005; 102: 224–5.
4. Turner E. H., Matthews A. M., Linardatos E., et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008; 358: 252–60.
5. Rising K., Bacchetti P., Bero L. Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation. PLoS Med. 2008; 5: e217.
6. Lenzer J. Drug secrets: what the FDA isn’t telling. Slate. 2005 Sept 27.
7. Rennie D. When evidence isn’t: trials, drug companies and the FDA. J Law Policy. 2007 July: 991–1012.
8. Chalmers I. From optimism to disillusion about commitment to transparency in the medicoindustrial complex. J R Soc Med. 2006; 99: 337–41.
9. Scherer R. W., Langenberg P., von Elm E. Full publication of results initially presented in abstracts. Cochrane Database Syst. Rev. 2007; 2: MR000005.
10. MacLean C. H., Morton S. C., Ofman J. J., et al. How useful are unpublished data from the Food and Drug Administration in meta-analysis? J Clin Epidemiol. 2003; 56: 44–51.
11. Goldacre B. Bad Pharma. London: Fourth Estate; 2012.
12. Chalmers I. Underreporting research is scientific misconduct. JAMA. 1990; 263: 1405–8.
13. Danish Association of the Pharmaceutical Industry. [Revised collaborative agreement between the Medical Association and the Danish Association of the Pharmaceutical Industry about clinical trials and non-intervention studies]. 2010 June 1.
14. G?tzsche P. C., J?rgensen A. W. Opening up data at the European Medicines Agency. BMJ. 2011; 342: d2686.
15. Wikipedia. Rimonabant. Available online at: http://en.wikipedia.org/wiki/Rimonabant (accessed 17 January 2013).
16. World Medical Association. Declaration of Helsinki – ethical principles for medical research involving human subjects. 2008.
17. G?tzsche P. C. Why we need easy access to all data from all clinical trials and how to accomplish it. Trials. 2011; 12: 249.
18. Topol E. J. Failing the public health – rofecoxib, Merck, and the FDA. N Engl J Med. 2004; 351: 1707–9.
19. Lenzer J. FDA is incapable of protecting US ‘against another Vioxx’. BMJ. 2004; 329: 1253.
20. Anonymous. Institute of Medicine urges reforms at FDA. Lancet. 2006; 368: 1211.
21. Relman A. S., Angell M. America’s other drug problem: how the drug industry distorts medicine and politics. The New Republic. 2002 Dec 16: 27–41.
22. Carpenter D. Drug-review deadlines and safety problems (authors’ reply). N Engl J Med. 2008; 359: 96–8.
23. Moore T. J. Deadly Medicine: why tens of thousands of heart patients died in America’s worst drug disaster. New York: Simon & Schuster; 1995.
24. Cowley A. J., Skene A., Stainer K., et al. The effect of lorcainide on arrhythmias and survival in patients with acute myocardial infarction: an example of publication bias. Int J Cardiol. 1993; 40: 161–6.
25. EMA. European Medicines Agency Widens Public Access to Documents. Press release. 2010 Nov 30.
26. Regulation (EC) № 1049/2001 of the European Parliament and of the Council of 30 May 2001 regarding public access to European Parliament, Council and Commission documents. Official Journal of the European Communities. 2001; L145: 43–8.
27. Hawkes N. Lobby groups call for closure of ‘revolving door’ between drug regulators and industry. BMJ. 2011; 343: d8335.
28. European Medicines Agency. Access to clinical-trial data and transparency. Workshop report. 2012. Available online at: www.ema.europa.eu/docs/en_GB/document_library/Report/2012/12/WC500135841.pdf (accessed December 2012).
29. Editorial. [Straight talk]. Information. 2004 June 30.
30. Alfter B., Teugels M., Bouma J. Media lift lid on secret reports on drug side-effects. Euobserver. 2008 Oct 22.
31. Abraham J. Science, Politics and the Pharmaceutical Industry. London: UCL Press; 1995.
32. G?tzsche P. C. UK drug regulator destroys all evidence after 15 years. BMJ. 2011; 343: d4203.
33. Juni P., Reichenbach S., Egger M. COX 2 inhibitors, traditional NSAIDs, and the heart. BMJ. 2005; 330: 1342–3.
34. Caldwell B., Aldington S., Weatherall M., et al. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med. 2006; 99: 132–40.
35. Mundy A. Dispensing with the Truth. New York: St. Martin’s Press; 2001.
36. Avorn J. Powerful Medicines: the benefits, risks, and costs of prescription drugs. New York: Vintage Books; 2005.
37. J?rgensen A. W. Robustness of results and conclusions in systematic reviews, trials and abstracts [PhD thesis]. Copenhagen: University of Copenhagen; 2011.
38. Connolly H. M., Crary J. L., McGoon M. D., et al. Valvular heart disease associated with fenfluraminephentermine. N Engl J Med. 1997; 337: 581–8.
39. Mullard A. Mediator scandal rocks French medical community. Lancet. 2011; 377: 890–2.
40. Mintzes B. New UK guidance on industry – health professional collaboration. BMJ. 2012; 344: e3952.
41. Padwal R., Kezouh A., Levine M., et al. Long-term persistence with orlistat and sibutramine in a population-based cohort. Int J Obes (Lond). 2007; 31: 1567–70.
42. Colman E., Golden J., Roberts M., et al. The FDA’s assessment of two drugs for chronic weight management. N Engl J Med. 2012; 367: 1577–9.
43. Dahl C. F., Allen M. R., Urie P. M., et al. Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals. BMC Med. 2008; 6: 3.